Governance Logic of the Dilemma in Medication Assurance of Rare Disease Under the Framework of "Cross-Border Enpowerment"&#x02014;&#x02014;Taking the Neurofibromatosis Type 1 as a Case

doi:10.19546/j.issn.1674-3830.2024.4.007

China Health Insurance ›› 2024, Vol. 0 ›› Issue (4) : 49-56. DOI: 10.19546/j.issn.1674-3830.2024.4.007

Governance Logic of the Dilemma in Medication Assurance of Rare Disease Under the Framework of "Cross-Border Enpowerment"——Taking the Neurofibromatosis Type 1 as a Case

Author information +

History +

Abstract

In recent years, the medication assurance of rare diseases in China has been significantly improved, with some diseases transitioning from "no drug supply" to "including drugs into basic medical insurance list". The study takes the neurofibroma type 1 as a case study, constructing an explanatory framework of "cross-border empowerment" in order to analyze the governance logic of breaking through the dilemma. This study found that in the field of market failures such as rare disease drugs, the government empowers market players by enacting favorable public policies, which effectively motivates them to take the initiative, while the market empowers other governance bodies and facilitates the formation of frequent interaction behaviors among multiple players across the border. The results of the interaction positively empower market players again, which to some extent effectively compensates for the market failures, and overcomes the dilemmas of medication assurance of rare diseases.

Key words

rare diseases / medication assurance / market failure / cross-border empowerment

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Governance Logic of the Dilemma in Medication Assurance of Rare Disease Under the Framework of "Cross-Border Enpowerment"——Taking the Neurofibromatosis Type 1 as a Case[J]. China Health Insurance. 2024, 0(4): 49-56 https://doi.org/10.19546/j.issn.1674-3830.2024.4.007

References

[1] 李莹.关于我国罕见病相关政策制定的探讨——基于罕见病群体生活状况调研的分析[J].中国软科学,2014(02):77-89.
[2] 新华社.中国罕见病诊疗服务信息系统已登记病例约78万例[EB/OL].(2023-10-22)[2023-12-15].https://www.gov.cn/yaowen/liebiao/202310/content_6910842.htm.
[3] 张伟涛.平等权视阈下罕见病的医疗保障[J].理论探索,2014(05):117-120.
[4] 中华人民共和国中央人民政府.健康路上,一个都不能少[EB/OL].(2016-11-24)[2023-12-15].https://www.gov.cn/xinwen/2016-11/24/content_5136746.htm.
[5] 中华人民共和国中央人民政府.中共中央国务院关于深化医疗保障制度改革的意见[EB/OL].(2020-03-05)[2023-12-15].https://www.gov.cn/zhengce/2020-03/05/content_5487407.htm.
[6] 李丹阳.政策网络理论视野下的中国“孤儿药”问题[J].学术研究,2014(04):50-53+159.
[7] 2024中国罕见病行业趋势观察报告[R].2024中国罕见病行业趋势观察报告[R].北京:北京病痛挑战基金会,2024:1-55.
[8] 基本医保对罕见病用药可及性的影响——医保纳入后患者用药负担情况研究[R].基本医保对罕见病用药可及性的影响——医保纳入后患者用药负担情况研究[R].北京:北京病痛挑战基金会,2024:1-18.
[9] 肖建华,王超群.罕见病防治和保障的支持体系:台湾的经验与启示[J].社会保障研究,2018(02):92-105.
[10] 顾一纯,黄镇,张琴华等.我国香港特别行政区罕见病用药保障政策[J].中国卫生资源,2021,24(06):636-640.
[11] 顾一纯,赵天保,张琴华,等.我国罕见病药品保障典型模式[J].中国卫生资源,2021,24(06):625-630.
[12] 张晓星,周婷婷,潘杰.国内外罕见病用药保障模式的评述[J].中国卫生政策研究,2020,13(11):18-23.
[13] 龚曦,王红波.整体性治理视域下多层次医疗保障体系的概念厘定、发展困境及路径选择[J].中国卫生政策研究, 2024, 17(02): 1-8.
[14] 何阿妹,徐源,宋捷等.国家医保谈判药品中罕见病用药落地情况分析——以20种罕见病用药为例[J].中国医疗保险,2023(09):18-26.
[15] 国家卫健委医政司.国家卫生健康委办公厅关于印发儿童血液病、恶性肿瘤相关12个病种诊疗规范(2021年版)的通知[EB/OL].(2021-05-13)[2023-12-15].http://www.nhc.gov.cn/yzygj/s7659/202105/3c18fec8a37d452b82fe93e2bcf3ec1e.shtml.
[16] 王智超,李青峰.Ⅰ型神经纤维瘤病临床诊疗专家共识(2021版)[J].中国修复重建外科杂志,2021,35(11):1384-1395.
[17] 国家卫健委医政司.关于公布第二批罕见病目录的通知[EB/OL].(2023-09-20)[2023-12-15].http://www.nhc.gov.cn/yzygj/s7659/202309/19941f5eb0994615b34273bc27bf360d.shtml.
[18] 国家医疗保障局.国家医保局人力资源社会保障部印发2023年版国家医保药品目录.[EB/OL].(2023-12-13)[2023-12-15].http://www.nhsa.gov.cn/art/2023/12/13/art_14_11671.html.
[19] GROSS A M,WOLTERS P L, DOMBI E, et al.Selumetinib in children with inoperable plexiform neurofibromas[J].The New England journal of medicine,2020,382(15):1430-1432.
[20] 国家卫健委医政司.关于公布第一批罕见病目录的通知[EB/OL].(2018-06-08)[2023-12-15].http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml.
[21] 国家卫健委医政司.关于印发罕见病目录制订工作程序的通知[EB/OL]..(2023-12-15)[2018-06-05].http://www.nhc.gov.cn/yzygj/s7659/201806/927defed71934ec8b032ccfca0afe0fb.shtml.
[22] 国家卫健委.关于政协第十四届全国委员会第一次会议第03130号(医疗卫生类268号)提案答复的函[EB/OL].(2023-09-28)[2023-12-15].http://www.nhc.gov.cn/wjw/tia/202309/387c2f7dafcb4516808518a413b1e15c.shtml.
[23] 杨宏山,赵远跃.权威引领与行动赋能:城市跨界治理的整合机制——基于北京城市基层治理的案例考察[J].云南行政学院学报,2023,25(05):41-50+2.
[24] 马亮.新一代人工智能技术赋能国家治理现代化的前景分析[J].国家治理,2024(01):29-33.
[25] 李山,周业军,王丛虎.数字化赋能公共资源交易智能监管[J].中国招标,2023(02):48-50.
[26] 张震宇,侯冠宇.新质生产力赋能中国式现代化的历史逻辑、理论逻辑与现实路径[J/OL].当代经济管理,https://link.cnki.net/urlid/13.1356.F.20240227.1519.002.
[27] 杨涛,张昊.国外罕见病药物研发激励制度及启示[J].中国药师,2020,23(08):1612-1614+1647.
[28] 孙柏瑛,周保民.政府注意力分配研究述评:理论溯源、现状及展望[J].公共管理与政策评论,2022,11(05):156-168.
[29] 布赖恩·琼斯.再思民主政治中的决策制定:注意力、选择和公共政策[M].北京:北京大学出版社,2010:9-11.
[30] 国家医疗保障局.国家医保局2023年国家基本医疗保险、工伤保险和生育保险药品目录调整新闻发布会实录[EB/OL].(2023-12-23)[2023-12-15].http://www.nhsa.gov.cn/art/2023/12/13/art_14_11684.html.
[31] 国家药品监督管理局.国家药品监督管理局国家卫生健康委员会关于优化药品注册审评审批有关事宜的公告(2018年第23号)[EB/OL].(2018-05-23)[2023-12-15].https://www.nmpa.gov.cn/xxgk/ggtg/ypggtg/ypqtggtg/20180523110601517.html.
[32] 娄宇,王逸伦.罕见病立法国际比较与启示——基于“适度保障”和“倾斜保障”原则的法律制度构建[J].中国医疗保险,2023(09):5-17.
[33] 福建省卫健委.国家卫生健康委办公厅关于印发儿童血液病、恶性肿瘤相关12个病种诊疗规范(2021年版)的通知[EB/OL].(2021-05-14)[2024-04-16].https://wjw.fujian.gov.cn/xxgk/fgwj/gjwj/202105/t20210514_5594862.htm.